Outcome of Repeat Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081821" target="_blank" >RIV/00023001:_____/21:00081821 - isvavai.cz</a>
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S1053077021001968?token=2CE740051EA6238C88F705B56009EB19600E3F1603F084D6B9C35C69F10D4097A2B80D66B3AFD86CBD5012EADC630FF1&originRegion=eu-west-1&originCreation=20211213152504" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1053077021001968?token=2CE740051EA6238C88F705B56009EB19600E3F1603F084D6B9C35C69F10D4097A2B80D66B3AFD86CBD5012EADC630FF1&originRegion=eu-west-1&originCreation=20211213152504</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1053/j.jvca.2021.03.001" target="_blank" >10.1053/j.jvca.2021.03.001</a>
Alternative languages
Result language
angličtina
Original language name
Outcome of Repeat Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock
Original language description
Objective: Data on patients requiring a second run of venoarterial extracorporeal membrane oxygenation (VA-ECMO) support in patients affected by postcardiotomy cardiogenic shock (PCS) are very limited. The authors aimed to investigate the effect of a second run of VA-ECMO on PCS patient survival. Design: Retrospective analysis of an international registry. Setting: Multicenter study, tertiary university hospitals. Participants: Data on adult PCS patients receiving a second run of VA-ECMO. Measurements and Main Results: A total of 674 patients with a mean age of 62.9 +/- 12.7 years were analyzed, and 21 (3.1%) patients had a second run of VA-ECMO. None of them required more than two VA-ECMO runs. The median duration of VA-ECMO therapy was 135 hours (interquartile range [IQR] 61-226) in patients who did not require a VA-ECMO rerun. In the rerun VA-ECMO group the median overall duration of VA-ECMO therapy was 183 hours (IQR 107-344), and the median duration of the first run was 114 hours (IQR 66-169). Nine (42.9%) of the patients who required a second run of VA-ECMO died during VA-ECMO therapy, whereas five (23.8%) survived to hospital discharge. No differences between patients treated with single or second VA-ECMO runs were observed in terms of hospital mortality and late survival. In patients requiring a second VA-ECMO run, the actuarial survival estimates at three and 12 months after VA-ECMO weaning were 23.8% +/- 9.3% and 19.6% +/- 6.4%, respectively. Conclusions: Repeat VA-ECMO therapy is a valid treatment strategy for PCS patients. Early and late survivals are similar between patients who have undergone a single or second run of VA-ECMO. (C) 2021 Elsevier Inc. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of cardiothoracic and vascular anesthesia
ISSN
1053-0770
e-ISSN
—
Volume of the periodical
35
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
3620-3625
UT code for WoS article
000719123300020
EID of the result in the Scopus database
2-s2.0-85103954557